Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous anifrolumab for moderate-to-severe SLE (Tulip SC, Japan)
jRCT2071210076Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Anifrolumab arm with Placebo arm (2 arms). Primary endpoint: BICLA response at week 52. Started Mar 2022; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2071210076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210076.